Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coronary Microvascular Dysfunction May Predict Heart Disease in Rheumatoid Arthritis

Kurt Ullman  |  Issue: December 2020  |  December 14, 2020

AlexLMX / shutterstock.com

AlexLMX / shutterstock.com

Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population.

Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research suggests coronary microvascular dysfunction may be a predictor of heart disease in this population, as has been shown in people with diabetes and the general population. Researchers have not yet been able to pinpoint what clinicians should measure to capture excess cardiovascular risk among patients with RA.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Higher Risk of Mortality

“When we think about CVD we usually focus on coronary arteries and cholesterol,” says lead author Katherine Liao, MD, MPH, associate professor of medicine at Harvard Medical School, Boston. “Researchers have found that in both diabetes and the general population, dysfunction of the smaller vessels in the heart, known as the coronary micro­vasculature, leads to a higher risk for cardiac mortality.”

The researchers compared RA patients with those who have diabetes, a group of patients in whom coronary microvascular dysfunction is an established cause of cardiac mortality. They looked at whether microvascular dysfunction in the heart exists in patients with RA. If so, is it tied to cardiac and all-cause mortality?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Study Parameters

Dr. Liao

Dr. Liao

The researchers undertook a retrospective cohort study using data obtained from all patients undergoing stress myocardial perfusion positron emission tomography (PET) scans between 2006 and 2017 at Brigham and Women’s Hospital, Boston.

All patients with a normal stress test were included in the study. Patients with known coronary artery disease, a history of myocardial infarction, coronary revascularization, transplantation or moderate to severe valve disease were excluded. Others not included were those with abnormal PET scans showing they already had obstructive coronary artery disease.

Pertinent patient information, such as biologic and non-biologic disease-modifying anti-rheumatic drug use, was obtained through medical records. Data on diabetes treatments, other traditional CVD risk factors, as well as medications used for primary and secondary CVD prevention, were also added. Coronary flow reserve (CFR; the ability of the coronaries to increase blood flow under stress) was calculated using the registry. Coronary microvascular dysfunction was defined as CFR <2.0.

“The data we use to calculate CFR and detect [coronary microvascular dysfunction] are, in many cases, obtained routinely as part of the cardiac stress test,” says Dr. Liao. “Since the main reason to undergo a stress test is to look for blockages in the coronary arteries and not microvascular function, we are not routinely pulling data on [coronary microvascular dysfunction].”

The cohort included 73 subjects with RA and 441 with diabetes who met the inclusion or exclusion criteria. The mean age was similar in both groups: 63 years. The proportion of women was higher in RA than in diabetes (73% vs. 56%, respectively). Those with diabetes had higher prevalence of hypertension and dyslipidemia. Eighteen percent had concurrent RA and diabetes.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Cardiovascular diseasecoronary microvascular disease

Related Articles

    The Heart-SCC Puzzle

    May 1, 2009

    Identifying and treating cardiac involvement in systemic sclerosis can be a challenge

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

    February 18, 2021

    Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    February 16, 2021

    In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences